{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:09:35Z","timestamp":1771952975509,"version":"3.50.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Ketamine is recommended as an opioid-sparing adjunct for sickle cell disease (SCD)-related pain management. Little is known regarding its use in hospitalized youth with SCD. We aimed to describe trends in ketamine administration and examine associations between ketamine administration and outcomes in hospitalized youth with SCD. We conducted a cross-sectional, multicenter study examining hospital admissions for youth with SCD from 44 children\u2019s hospitals in the United States from 2016 to 2023. Youth aged \u22656 months with SCD were identified using International Classification of Diseases tenth revision codes. Exposures included age, sex, race, payor, childhood opportunity index, hydroxyurea administration, and concomitant methadone, buprenorphine, or gabapentinoid administration. The primary outcome was ketamine administration during admission. Secondary outcomes included length of stay, days on IV opioids, all-cause 14-day readmission rates, and intensive care unit stays during admissions with ketamine administered during the first 3 days of hospitalization (early) and hospital day 4 or later (late). From 2016 to 2023, 4.5% (n = 3391) of admissions for patients with SCD included ketamine administration, with prevalence increasing from 2.3% in 2016 to 5.7% in 2023 (P&amp;lt; .001). Age groups \u226512 years and the year \u22652019 was associated with increased odds of ketamine administration. Admissions with ketamine administration were also more likely to have administration of methadone and hydroxyurea. Early vs late ketamine administration was associated with shorter length of stay and fewer parental opioid days, indicating randomized controlled studies are needed to determine not only which patients benefit from ketamine but also the impact of early administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016826","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T21:01:35Z","timestamp":1764795695000},"page":"1106-1113","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Increasing ketamine administration in children\u2019s hospitals for youth with sickle cell disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-7824","authenticated-orcid":false,"given":"Ashley M.","family":"Jenkins","sequence":"first","affiliation":[{"name":"1Department of Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, NY"},{"name":"2Department of Pediatrics, School of Medicine and Dentistry, University of Rochester, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Hendry","sequence":"additional","affiliation":[{"name":"3School of Medicine and Dentistry, University of Rochester, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5823-0218","authenticated-orcid":false,"given":"Alexandra","family":"Power-Hays","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"},{"name":"5Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Valentino","sequence":"additional","affiliation":[{"name":"6Department of Pharmacy, School of Medicine and Dentistry, University of Rochester, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7778-5887","authenticated-orcid":false,"given":"Matthew","family":"Hall","sequence":"additional","affiliation":[{"name":"7Children's Hospital Association, Lenexa, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Kyler","sequence":"additional","affiliation":[{"name":"8Divisions of Hospital Medicine and Clinical Pharmacology, Children's Mercy, Kansas City, MO"},{"name":"9Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6188-2658","authenticated-orcid":false,"given":"James W.","family":"Antoon","sequence":"additional","affiliation":[{"name":"10Division of Hospital Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-8499","authenticated-orcid":false,"given":"Sonya","family":"Tang Girdwood","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH"},{"name":"11Divisions of Hospital Medicine and Translation and Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-8949","authenticated-orcid":false,"given":"Jennifer L.","family":"Goldman","sequence":"additional","affiliation":[{"name":"9Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, MO"},{"name":"12Divisions of Pediatric Infectious Diseases and Clinical Pharmacology, Children's Mercy, Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armand N.","family":"Morel","sequence":"additional","affiliation":[{"name":"13Department of Anesthesiology, Children's Mercy, Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-7379","authenticated-orcid":false,"given":"Timothy J.","family":"Savage","sequence":"additional","affiliation":[{"name":"14Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"15Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"16Division of Infectious Diseases, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas E.","family":"Orth","sequence":"additional","affiliation":[{"name":"17Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha M.","family":"Archer","sequence":"additional","affiliation":[{"name":"18Division of Medical Oncology, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"},{"name":"19Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"1","key":"2026022411371778600_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.21570","article-title":"The number of people with sickle-cell disease in the United States: national and state estimates","volume":"85","author":"Brousseau","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"2026022411371778600_bib2","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"GBD 2021 Sickle Cell Disease Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026022411371778600_bib3","author":"Fingar","year":"2019"},{"issue":"12","key":"2026022411371778600_bib4","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026022411371778600_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1526-4637.2006.00252.x","article-title":"Pain experience of children with sickle cell disease who had prolonged hospitalizations for acute painful episodes","volume":"9","author":"Jacob","year":"2008","journal-title":"Pain Med"},{"issue":"4","key":"2026022411371778600_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00043426-200304000-00008","article-title":"Management of vaso-occlusive pain in children with sickle cell disease","volume":"25","author":"Jacob","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"2026022411371778600_bib7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/mol.51.4.583","article-title":"Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors","volume":"51","author":"Cai","year":"1997","journal-title":"Mol Pharmacol"},{"issue":"5","key":"2026022411371778600_bib8","first-page":"456","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists","volume":"43","author":"Schwenk","year":"2018","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"2026022411371778600_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1515\/sjpain-2017-0140","article-title":"Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial","volume":"18","author":"Lubega","year":"2018","journal-title":"Scand J Pain"},{"issue":"2","key":"2026022411371778600_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/acem.14382","article-title":"Ketamine administration for acute painful sickle cell crisis: a randomized controlled trial","volume":"29","author":"Alshahrani","year":"2022","journal-title":"Acad Emerg Med"},{"issue":"2","key":"2026022411371778600_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/pr.2017.197","article-title":"Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease","volume":"83","author":"Nobrega","year":"2018","journal-title":"Pediatr Res"},{"key":"2026022411371778600_bib12","unstructured":"Pediatric Health Information Systems Database (PHIS). Accessed 10 December 2025. https:\/\/www.childrenshospitals.org\/Programs-and-Services\/Data-Analytics-and-Research\/Pediatric-Analytic-Solutions\/Pediatric-Health-Information-System."},{"issue":"2","key":"2026022411371778600_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/1475-6773.13257","article-title":"Performance of ICD-10-CM diagnosis codes for identifying children with sickle cell anemia","volume":"55","author":"Reeves","year":"2020","journal-title":"Health Serv Res"},{"issue":"11","key":"2026022411371778600_bib14","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1377\/hlthaff.2014.0679","article-title":"The child opportunity index: improving collaboration between community development and public health","volume":"33","author":"Acevedo-Garcia","year":"2014","journal-title":"Health Aff"},{"issue":"2","key":"2026022411371778600_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/AJP.0b013e3181b511ab","article-title":"Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series","volume":"26","author":"Zempsky","year":"2010","journal-title":"Clin J Pain"},{"issue":"3","key":"2026022411371778600_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31486\/toj.22.0011","article-title":"Ketamine as an analgesic adjunct for opioid-induced hyperalgesia in a patient with a sickle cell pain episode","volume":"22","author":"Martinez","year":"2022","journal-title":"Ochsner J"},{"issue":"2","key":"2026022411371778600_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/15360288.2013.788599","article-title":"Oral ketamine for sickle cell crisis pain refractory to opioids","volume":"27","author":"Jennings","year":"2013","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"5","key":"2026022411371778600_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00277-013-1954-3","article-title":"Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature","volume":"93","author":"Uprety","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2026022411371778600_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/15360288.2018.1468383","article-title":"Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: a case series","volume":"32","author":"Palm","year":"2018","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"8","key":"2026022411371778600_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/01612840.2018.1443530","article-title":"Stigma of sickle cell disease: a systematic review","volume":"39","author":"Bulgin","year":"2018","journal-title":"Issues Ment Health Nurs"},{"issue":"5","key":"2026022411371778600_bib21","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1192\/bjo.2019.52","article-title":"Exploring patients\u2019 and carers\u2019 views about the clinical use of ketamine to inform policy and practical decisions: mixed-methods study","volume":"5","author":"Jilka","year":"2019","journal-title":"BJPsych Open"},{"issue":"5","key":"2026022411371778600_bib22","doi-asserted-by":"crossref","first-page":"e30254","DOI":"10.1002\/pbc.30254","article-title":"Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease","volume":"70","author":"Harris","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2026022411371778600_bib23","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/pm\/pnac094","article-title":"Early initiation of sub-anesthetic ketamine infusion in adults with vaso-occlusive crises is associated with greater reduction in sickle cell pain intensity: a single center\u2019s experience","volume":"23","author":"Kenney","year":"2022","journal-title":"Pain Med"},{"issue":"10","key":"2026022411371778600_bib24","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1097\/j.pain.0000000000003262","article-title":"High-impact chronic pain in sickle cell disease: insights from the pain in Sickle Cell Epidemiology Study (PiSCES)","volume":"165","author":"Jagtiani","year":"2024","journal-title":"Pain"},{"issue":"1","key":"2026022411371778600_bib25","doi-asserted-by":"crossref","first-page":"2055102920917250","DOI":"10.1177\/2055102920917250","article-title":"Prevalence and predictors of chronic pain intensity and disability among adults with sickle cell disease","volume":"7","author":"Matthie","year":"2020","journal-title":"Health Psychol Open"},{"issue":"3","key":"2026022411371778600_bib26","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jpainsymman.2011.06.003","article-title":"Ketamine infusion for sickle cell crisis pain in an adult","volume":"42","author":"Meals","year":"2011","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"2026022411371778600_bib27","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1097\/MPH.0000000000002290","article-title":"Low-dose ketamine infusion for pediatric hematology\/oncology patients: case series and literature review","volume":"44","author":"Yu","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026022411371778600_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajem.2024.10.028","article-title":"Trends and hospital practice variation for analgesia for children with sickle cell disease with vaso-occlusive pain episodes: an 11-year analysis","volume":"86","author":"Eltorki","year":"2024","journal-title":"Am J Emerg Med"},{"key":"2026022411371778600_bib29","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2147\/JPR.S507983","article-title":"Exploring perceived barriers and facilitators for implementing acute pain clinical trials: a mixed-methods analysis of ketamine infusions for sickle cell pain","volume":"18","author":"Kenney","year":"2025","journal-title":"J Pain Res"},{"issue":"2","key":"2026022411371778600_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jpainsymman.2013.03.012","article-title":"The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease","volume":"47","author":"Tawfic","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"2026022411371778600_bib31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.23736\/S0375-9393.21.15707-4","article-title":"Patient-controlled analgesia in sickle-cell disease painful vaso-occlusive crises: should we add ketamine to morphine?","volume":"87","author":"Zuccarini","year":"2021","journal-title":"Minerva Anestesiol"},{"issue":"1","key":"2026022411371778600_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12916-018-1071-1","article-title":"Informing real-world practice with real-world evidence: the value of PRECIS-2","volume":"16","author":"Neta","year":"2018","journal-title":"BMC Med"},{"issue":"1","key":"2026022411371778600_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13063-023-07313-0","article-title":"Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis","volume":"24","author":"Zatzick","year":"2023","journal-title":"Trials"},{"issue":"6","key":"2026022411371778600_bib35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jhm.13322","article-title":"Disparities in pediatric hospital use during transition to adult healthcare for young adults with childhood-onset chronic conditions","volume":"19","author":"Jenkins","year":"2024","journal-title":"J Hosp Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1106\/2503242\/blooda_adv-2025-016826-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1106\/2503242\/blooda_adv-2025-016826-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:37:26Z","timestamp":1771951046000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1106\/556935\/Increasing-ketamine-administration-in-children-s"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016826","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,12]]}}}